Glenmark Pharmaceuticals USA to launch sodium phosphates injection
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Subscribe To Our Newsletter & Stay Updated